Seer is Delivering Clear Progress Against its Strategic Plan and Maintaining Focus on Cost Discipline, Governance Rigor and Product Innovation
Highly Qualified, Independent and Accountable Board Has Taken Decisive Action to Advance Stockholders' Best Interests
Board Urges Stockholders to Vote "FOR" ONLY Seer's Director Nominees on the BLUE Proxy Card
REDWOOD CITY, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) ("Seer" or the "Company") today filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on July 28, 2026. Stockholders as of May 29, 2026 will be entitled to vote at the Annual Meeting.
Highlights of the presentation include:
Seer has pioneered a new market for deep, unbiased proteomics and is now uniquely positioned to power the next era of AI-driven precision medicine.
-
Category-leading technology capable of delivering significantly more data to train foundation models and reveal deeper insights than other proteomic platforms
-
Landmark population-scale studies and strategic collaborations are already underway, marking an acceleration point in Seer's commercial opportunity
-
Robust innovation pipeline, including next-generation detector, has potential to meaningfully expand the end market for proteomics beyond mass spectrometry users
-
Substantial and fast-growing proteomics market could reach $23 billion total addressable market opportunity by 20341
-
Seer is delivering demonstrable progress against the goals outlined at its IPO despite a sector-wide downturn, and the Company's commercial inflection point is now approaching.
-
Focus on cost discipline has led to meaningful reductions in SG&A and R&D expenses each year since 2023 and 36% decrease in annual cash burn2 since 2022
-
Installed base has grown at a 62% CAGR since 2021,3 supported by partnerships with every major mass spectrometry platform
-
Cumulative publications doubled over the last year for a total of 84 peer-reviewed publications since 2022,4 underscoring scientific community's confidence in the platform
-
Product launches since 2021 have already increased platform throughput by ~10x, with additional launches on the horizon
-
With over 235 patent applications and issued patents, Seer is the leader in the category it created, and as industry validation continues to grow, the Company is ready to scale
-
Seer's highly qualified, independent Board is actively engaged and accountable to advancing stockholders' best interests.
-
Directors bring deep, highly relevant healthcare industry experience and life science tools expertise, and a majority also have financial backgrounds
-
Five of seven directors are independent, and average tenure of 5.5 years5 reflects commitment to ongoing refreshment
-
Directors collectively own 17% of Seer's total shares outstanding6
-
Board has a clear track record of returning capital and protecting stockholder interests, including:
-
Authorizing $50 million in total share repurchases, with $25.5 million remaining in the program;7
-
Overseeing ~75% decrease in stock-based compensation since 2023 to annualized run rate of $8.5M in 2026;
-
Maintaining cash position of ~$220 million with no debt, providing ample runway to fund platform commercialization; and
-
Adopting a tax benefit preservation plan to ensure $262.4 million of federal net operating loss carryforwards remain available to benefit stockholders long term8
-
-
Bradley Radoff and Michael Torok are running a self-interested campaign to force an early sale of the Company and strip it of its own cash.
-
Campaign lacks actionable ideas for value creation
-
Radoff and Torok lack credibility as potential buyers, providing no evidence of committed financing or indicating any desire to put their own capital at risk
-
The Board carefully reviewed, discussed and unanimously rejected all of Radoff and Torok's proposals in consultation with its independent financial and legal advisors
-